{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-022318","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.940614+00:00","generated_at":"2026-05-16T20:24:11.092451+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Evofem posts Q3 2025 operating income of $1.0M; net sales up 10% YoY to $5.0M","bullets":["Net sales $5.0M in Q3 2025 vs $4.5M Q3 2024; operating income $1.0M vs loss of $2.4M.","Net loss attributable to common stockholders $1.7M ($0.01 per share) vs $2.4M ($0.02) prior year.","Total operating expenses decreased 42% to $4.0M, helped by $1.9M gain from change in Rush royalty estimate.","Terminated merger with Aditxt after stockholders did not approve the deal at Oct 20 special meeting.","Advancing manufacturing cost reduction targeting ~50% lower COGS for both PHEXX and SOLOSEC."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-022318","json":"https://secwatch.observer/filing/0001493152-25-022318.json","markdown":"https://secwatch.observer/filing/0001493152-25-022318.md","text":"https://secwatch.observer/filing/0001493152-25-022318.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000149315225022318/0001493152-25-022318-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000149315225022318/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:24:11.092451+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}